November 15, 2018
Dear Friends,
This was a monumental year at the Faustman Lab. We published long-term data on patients from the BCG clinical trial program who have been followed for at least five years. The results were published in Nature Vaccines and presented at eh 78th Scientific Sessions of the American Diabetes Association (ADA) as well as the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD). The positive feedback and media coverage was overwhelming. EASD even scheduled a press conference to announce the results. We also published the second edition of our book, BCG, TNF and Autoimmunity, which is based on the third international conference on BCG and autoimmune diseases. The 150 patient Phase II trial is also proceeding; all 150 patients have received at least two doses of BCG or placebo.
BCG is a generic vaccine that holds the promise of an affordable treatment option for type 1 diabetics -- for patients of all means. As you know, we are operating outside the traditional funding models for clinical trials because BCG is a generic drug. All of our funding comes from private philanthropies and individuals who are impacted by the disease. We are the open source approach to clinical trials -- a clinical trial by the people for the people.
We have a lot of work to do before we can bring BCG to market with an FDA approved indication for type 1 diabetes. We are also actively planning and enrolling new trials including a pediatric trial and an Expanded Access IND. Anything you can do to help us meet our fundraising goals and turn our full attention back to the research is appreciated.
With Kind regards,
Denise L. Faustman, MD, PhD
No comments:
Post a Comment